Which has the lower trailing P/E, ABT or VRTX?

VRTX has the lower trailing P/E: ABT trades at 36.79 and VRTX at 32.13. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ABT or VRTX?

Over the past five years, VRTX grew revenue faster — ABT at a 2.98% CAGR versus VRTX at 13.57%.

Does ABT or VRTX pay a bigger dividend?

ABT pays a dividend (2.17% yield), while VRTX has no payments in the available dividend history.

Is ABT or VRTX more profitable?

VRTX runs the higher net margin — ABT at 11.65% versus VRTX at 34.89%.

How have ABT and VRTX total returns compared?

Over the past 10 years, ABT delivered 12.06% and VRTX delivered 18.87% annualized total return. Past performance doesn't predict future results.

Abbott Laboratories (ABT) vs Vertex Pharmaceuticals Incorporated (VRTX)

A side-by-side comparison of Abbott Laboratories and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 19, 2026. Differences are shown without an overall score or investment verdict.

ABT

Abbott Laboratories

$198.06B

$114.46HealthcareDelayed quote: Aug 19, 2026, 3:59 PM EDT

VRTX

Vertex Pharmaceuticals Incorporated

$140.12B

$552.06HealthcareAt close: Aug 19, 2026, 4:00 PM ET

Total return — ABT vs VRTX

growth of $100 · dividends reinvested · last 10y

ABT +219.9% (+12.3%/yr)VRTX +452.1% (+18.6%/yr)VRTX compounded faster over this window

ABT VRTX

ABT vs VRTX: by the numbers

•ABT is the larger company ($198.06B vs $140.12B market cap).
•VRTX trades at the lower trailing earnings multiple (32.13 vs 36.79 P/E), one valuation lens rather than an overall verdict.
•VRTX converts more revenue to profit (34.89% vs 11.65% net margin).
•VRTX grew revenue faster over the past five years (13.57% vs 2.98% CAGR).
•ABT pays a dividend (2.17% yield), while VRTX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	ABT	VRTX
P/E ratio	36.79	32.13
Forward P/E	20.75	29.41
P/S ratio	4.28	11.18
P/B ratio	3.90	6.97
EV / EBITDA	20.84	26.91
FCF yield	4.37%	2.69%

Profitability

Metric	ABT	VRTX
Gross margin	56.80%	86.04%
Operating margin	17.03%	38.59%
Net margin	11.65%	34.89%
ROE	10.61%	21.76%
ROIC	6.07%	17.33%

Dividends

Metric	ABT	VRTX
Dividend yield	2.17%	N/A
Payout ratio	66.31%	N/A

Growth (annualized)

Metric	ABT	VRTX
Revenue CAGR (5Y)	2.98%	13.57%
EPS CAGR (5Y)	8.22%	8.17%
FCF CAGR (5Y)	0.18%	16.39%
Total return CAGR (5Y)	0.07%	23.14%

Frequently asked

Which has the lower trailing P/E, ABT or VRTX?: VRTX has the lower trailing P/E: ABT trades at 36.79 and VRTX at 32.13. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ABT or VRTX?: Over the past five years, VRTX grew revenue faster — ABT at a 2.98% CAGR versus VRTX at 13.57%.
Does ABT or VRTX pay a bigger dividend?: ABT pays a dividend (2.17% yield), while VRTX has no payments in the available dividend history.
Is ABT or VRTX more profitable?: VRTX runs the higher net margin — ABT at 11.65% versus VRTX at 34.89%.
How have ABT and VRTX total returns compared?: Over the past 10 years, ABT delivered 12.06% and VRTX delivered 18.87% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABT analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

Abbott Laboratories P/E ratio Vertex Pharmaceuticals P/E ratio Abbott Laboratories dividend yield Abbott Laboratories ROE Vertex Pharmaceuticals ROE Abbott Laboratories operating margin Vertex Pharmaceuticals operating margin Abbott Laboratories revenue growth Vertex Pharmaceuticals revenue growth Abbott Laboratories free cash flow Vertex Pharmaceuticals free cash flow

Abbott Laboratories & Vertex Pharmaceuticals appear in these rankings

Highest Dividend Yield Stocks 25+ Year Dividend Growers Highest Operating Margin Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 19, 2026.